液氮冷冻治疗多发性跖疣的护理体会

总结了40例液氮冷冻治疗多发性跖疣的护理要点,包括治疗前、治疗中和治疗后护理.认为治疗前建立良好的护患关系、保持治疗室清洁舒适及正确评估患者是治疗成功的前提,治疗时熟练掌握操作技巧是治疗成功的关键,治疗后做好患者皮肤护理也是非常重要的一步.     

中药浸泡联合火针治疗多发性跖疣临床研究

目的：观察中药浸泡联合火针治疗多发性跖疣的临床研究。方法：将60例多发性跖疣患者,随机分成对照组和观察组,对照组(30例)采用中药浸泡治疗,1次/d,每次30min;观察组(30例)在对照组基础上联合火针治疗,其中火针每周1次,2组均治疗8周。观察2组的临床症状积分、疗效、不良反应率及复发率。结果：(1)临床疗效：治疗8周后,观察组的临床症状积分(2.86±2.63)明显低于对照组(4.72±2.60),观察组的有效率(79.31%)与对照组(51.72%)相比,差异有统计学意义(χ²=4.884,P<0.05);(2)复发率：观察组无复发病例(0.00%),对照组在15例痊愈及显效的患者中出现复发4例(26.67%),差异有统计学意义(P=0.018<0.05);(3)安全性：观察组中有2人,在火针治疗后出现施术部位的灼痛,但症状均可在1～3h内消失。对照组未见不良反应。2组的不良反应发生率差异无统计学意义(P=0.491>0.05)。结论：中药浸泡联合火针是治疗多发性跖疣安全、有效、经济的治疗选择。     

治疣汤泡洗联合液氮冷冻治疗跖疣热瘀互结证的疗效观察

目的 观察治疣汤泡洗联合液氮冷冻治疗跖疣热瘀互结证的疗效。方法 选取61例跖疣热瘀互结证患者随机分成2组,对照组28例予液氮冷冻治疗,1次/2周,观察组33例在对照组基础上加用治疣汤泡洗,1次/d,20 min/次,治疗2个月后比较疗效。结果 观察组皮损个数、大小评分均低于对照组,差异有统计学意义(P<0.05)。观察组总有效率87.9%,对照组总有效率64.3%,差异有统计学意义(P<0.05)。观察组疼痛发生率低于对照组,差异有统计学意义(P<0.05)。疗程结束后第4个月随访,对照组复发7例(25%);观察组复发2例(6%);两组复发率比较,差异有统计学意义(P<0.05)。结论 治疣汤外洗联合液氮冷冻治疗跖疣可提高疗效,改善疼痛,降低复发率。     

平阳霉素局部注射治疗多发性跖疣177例疗效观察

目的：探讨平阳霉素局部泥射治疗多发性跖疣（VP）的临床效果。方法：将177例多发性跖疣患者按照数字表法随机分为3组,观察组59例给予平阳霉素局部泥射治疗;对照组A组59例给予液氮冷冻治疗;对照组B组59例给予微波局部烧灼治疗。3组治疗1次/4w,共1～2次,治疗4w后若未见疣体脱落予第2次治疗,8w后并比较3组的临床效果。结果：随诊时间12周,观察组总有效率为98.31%,而显著的高于对照A组的76.27%(X2=12.9074,P＜0.05)及对照B组的74.58%(X2=14.1716,P＜0.05);177例患者随访1年,观察组总复发率3.39%,而显著的低于对照A组的15.25%(X2=5.9371,P＜0.05)及对照B组的16.95%(X2=14.1716, P＜0.05)。结论：平阳霉素局部泥射治疗多发性跖疣具有操作简单、疗效高、治疗费用低廉、复发率低、创面损伤小、不留瘢痕、感染率低、患者痛苦小、术后未见明显副作用等优点,是一种理想的治疗方法,而且值得临床大力推广应用。     

中药外洗联合火针治疗多发性跖疣的临床疗效

目的 研究中药外洗联合火针治疗多发性跖疣的临床疗效,为优化跖疣的临床治疗方案提供参考.方法 选取2020年10月至2021年7月北京市大兴区中西医结合医院皮肤科收治的100例多发性跖疣患者作为研究对象,按照随机数字表法分为观察组和对照组,各50例.观察组患者采用中药外洗联合火针治疗;对照组患者行火针治疗.比较两组患者治...     

异维A酸、匹多莫德联合液氮冷冻治疗多发性顽固性跖疣23例

目的总结异维A酸、匹多莫德联合液氮冷冻治疗多发性顽固性跖疣的疗效及安全性。方法服用常用剂量异维A酸、匹多莫德2个月,并配合冷冻方法,每2周1次。分别于第3、6个月随访。结果疗程结束后,所有患者全部临床治愈。第1次随访有3例复发,重复治疗有效;第2次随访无复发病例。合并用药未增加药物的不良反应,未发生局部皮肤感染、瘢痕等。结论异维A酸、匹多莫德联合液氮冷冻治疗多发性顽固性跖疣治愈率高,复发率低,安全有效。     

自体疣包埋术联合卡介苗多糖核酸治疗多发性跖疣疗效观察

将86例多发性跖疣患者随机分为治疗组和对照组,各43例。治疗组采用自体疣包埋术联合肌注卡介苗多糖核酸治疗。对照组单纯肌注卡介苗多糖核酸治疗。治疗结束后6周观察疗效,并随访6个月观察复发情况。结果治疗组痊愈率、有效率、复发率分别为52.2%、84.8%、4.3%;对照组分别为27.5%、62.5%、25.0%。两组痊愈率、有效率、复发率比较差异有统计学意义(P0.05)。自体疣包埋术联合卡介苗多糖核酸治疗多发性跖疣痛苦小、不良反应少、疗效好且复发率低,值得临床推广应用。     

重组人干扰素Y联合冷冻治疗跖疣的临床观察及护理

目的探讨重组人干扰素Y联合冷冻治疗跖疣的临床疗效及护理。方法将95例跖疣患者随机分为对照组45例和治疗组50例。对照组采用疣体冷冻治疗,治疗组在疣体基底部注射重组人干扰素Y的同时联合液氮冷冻治疗。两组均为7～10天治疗1次,3次为1疗程。结果对照组总有效率为51%,治疗组为88%,两组比较有显著性差异（P〈0.001）。结论重组人干扰素Y联合冷冻治疗跖疣是目前较好的治疗方法之一,且操作简便、安全、不留瘢痕。     

火针疗法联合祛疣方治疗多发性跖疣的疗效观察及对患者免疫功能的影响

目的 观察火针疗法联合祛疣方治疗多发性跖疣的临床疗效和对患者免疫功能的影响。方法 选取2018年6月-2020年10月在山东省威海市妇幼保健院、威海市立医院就诊的127例多发性跖疣患者,按照就诊先后顺序随机分为治疗69例和对照组58例。治疗组采用火针疗法联合祛疣方治疗,对照组采用液氮冷冻治疗,比较两组临床疗效及复发率,分别在治疗前及治疗结束后,应用酶联免疫吸附试验（ELISA）检测血清中白介素-2( IL-2) 、白介素-4( IL-4) 和γ干扰素( INF-γ) 的水平,并与36例健康人组比较。结果 （1）两组治疗后临床疗效及复发率比较,治疗组优于对照组,差异具有统计学意义（P＜0.05）。（2）两组细胞因子测定结果比较,治疗组治疗后 IL-2、4和INF-γ水平较治疗前明显上升,差异均有统计学意义(P＜0.05);对照组治疗后较治疗前水平略有上升(P＜0.05);两组治疗后比较,治疗组 IL-2、4和INF-γ水平明显优于对照组,差异具有统计学意义（P＜0.05）。结论 火针疗法联合祛疣方治疗多发性跖疣疗效显著,提高机体免疫功能,减少复发。     

0.2%5-氟尿嘧啶热溶液外泡治疗多发性跖疣

笔者于2003年7月至2005年7月对47例多发性跖疣患者采用0．2％5-氟尿嘧啶热溶液外泡治疗，取得良好疗效．现报告如下。     

中药辅助治疗重症急性胰腺炎的临床观察

目的观察常规西药加中药口服联合保留灌肠辅助治疗重症胰腺炎临床疗效。方法将80例患者随机分为试验组和对照组。对照组采用西医常规治疗,试验组在西医常规治疗的基础上,加用中药柴胡承气汤口服联合大承气汤保留灌肠。观察两组患者症状、体征、血白细胞计数、淀粉酶、器官功能障碍情况及病死率,比较两组总有效率。结果试验组治疗重症胰腺炎的总有效率明显高于对照组,差异有显著性(P<0.05)。试验组未见明确与中药治疗相关的严重不良反应。结论常规西药加中药口服联合灌肠辅助治疗重症急性胰腺炎,可显著提高疗效。     

慢性盆腔炎中药治疗的疗效观察及护理

目的：探讨中药治疗慢性盆腔炎的有效方法及护理。方法：按住院时间顺序将120例慢性盆腔炎患者分为观察组(80例)和对照组(40例)，观察组采用系列中药协定方，采取口服、保留灌肠及腹部热敷3种给药途径；对照组采用抗生素静脉滴注，加超短波理疗。结果：观察组疗效明显优于对照组。结论：采用这一系列中药治疗慢性盆腔炎，并辅以有效的护理是一种理想的治疗方案。     

中草药对香烟中烟雾毒害的解毒作用研究

目的：探讨中草药对香烟中烟雾毒害的化解疗效，为临床应用提供科学依据。方法：①动物实验：50只小鼠用灌服烟焦油制备模型，然后随机分为两组，模型对照组20只灌服5ml葡萄糖，中药实验组30只灌服中草药液解毒，观察两组动物的生存情况。②临床试验选择10例志愿者。选择168例有吸烟史的门诊及住院患者连续观察3个月，试验期间吸烟不减量并口服中草药液，观察临床症状、体证、X线胸片或CT、心电图ST—T变化、肝功能、血或尿常规等。结果：①动物实验中中药实验组存活率为93．3％（28／30只），模型对照组20只全部死亡。②临床试验中预试验时10例志愿者两组症状改善情况差异有显著性。168例吸烟者1个月后85例阵发性咳嗽、咯黑色黏痰等临床症状消除，2个月后123例症状消除，3个月后138例症状消除。84例心电图ST～T改变者中1个月内恢复21例，2个月恢复35例，3个月恢复45例。CT或X线胸片1个月有效89例，2个月有效140例，3个月有效150例。3个月中无一例肝功能、血常规、尿常规出现异常。结论：中草药液能消除香烟烟雾造成的临床症状，减轻毒害，促进心肺康复，稳定内环境，有明显效果和临床实用意义。     

Long-term use of combined conventional medicine and Chinese herbal medicine decreases the mortality risk of patients with lung cancer

BackgroundWe explored the effect of Chinese herbal medicine (CHM) on the long-term survival of lung cancer patients and hazard ratio (HR) and to analyse CHM herbs and formulas for lung cancer treatment.MethodsWe conducted a retrospective cohort study on diagnosed lung cancer patients in 2003–2016 from Taipei and Dalin Tzu Chi General Hospital Cancer Registry Database and from outpatient database from Chinese Medicine and Conventional Medicine Department. We categorised the patients into CHM user and CHM nonuser groups according to the CHM consumption time. After passing the proportional hazard assumption, we used the Cox PH model to calculate the groups’ survival hazard ratio (HR) and examine the statistical difference and effect of CHM on lung cancer survival.ResultsWe classified 2557 lung cancer patients into 1643 CHM nonusers and 228 CHM users. The CHM users had lower mortality than the CHM nonusers. With the multivariable Cox model, we observed that the CHM use was associated with 35% lower risk of mortality (adjusted HR: 0.65; 95% confidence interval: 0.51-0.76). Continuous CHM use of >180 days may further lessen the mortality risk by 64%. Finally, eight herbs and two formulas could significantly lower the mortality. After pairing the eight herbs for analysis, seven combinations could reduce the mortality better than only using one herb.ConclusionCHM users had significantly lower mortality than CHM nonusers. The longer the CHM use, the more the mortality HR declined. Glehnia littoralisF. Schmidt ex Miq., Polyporus umbellatus(Pers.) Fries and Trichosanthes kirilowii Maxim. possess a highly substantial anticancer activity compared with other herbs.     

中草药复杂方剂对慢性肾功能不全进展的影响

目的 探讨复杂配方的中草药制剂时对慢性功能不全进展的影响。方法 回顾性分析44例服中草药患者和49例未服过中草药患者病程初期、病程3个月时的血尿素氮(BUN)、血肌酐(Scr)水平变化;将两组患者同期的SUN、Scr水平进行对比。并将两组患者发现BUN、Scr开始升高至发展到Scr>600umol/L的时间进行对比。结果 两组患者病程3个月时的BUN、Scr水平均较病程初期明显升高(P相似文献   

布地奈德雾化吸入联合“冬病夏治”中药穴位贴敷法治疗儿童哮喘的临床效果分析

目的观察布地奈德雾化吸入联合"冬病夏治"中药穴位贴敷法治疗儿童哮喘的临床疗效。方法选取哮喘患儿80例,随机分为观察组和对照组各40例。对照组给予布地奈德吸入,观察组在对照组基础上加用"冬病夏治"中药穴位贴敷法治疗。比较2组患儿治疗前后临床症状改善情况、肺功能指标、血清炎症因子水平。结果观察组患儿临床症状改善时间显著短于对照组(P0.05)。2组患儿治疗后肺功能和血清炎性因子水平与治疗前比较均显著改善(P0.05),且观察组与对照组相比改善更显著(P0.05)。结论布地奈德雾化吸入联合"冬病夏治"中药穴位贴敷法治疗儿童哮喘效果良好,可显著提高临床疗效,降低血清炎症因子水平,改善肺功能。     

中药熏药联合辨证施膳治疗慢性盆腔炎病人效果观察

[目的]探讨中药熏药联合辨证施膳对慢性盆腔炎病人临床疗效。[方法]将93例病人按随机数字表法分为对照组46例和观察组47例。两组病人均采用常规抗生素治疗,观察组在常规抗生素治疗的基础上加用中药熏药联合辨证施膳,7d为1疗程,总共治疗2疗程。观察治疗前后疗效、症候评分、生活质量以评估病人症状改善情况。[结果]观察组的盆腔炎症状明显减轻,与对照组比较差异有统计学意义(P0.05);观察组证候评分低于对照组(P0.05);治疗后观察组生存质量评分高于对照组(P0.05)。[结论]中药熏药联合辨证施膳治疗慢性盆腔炎能减轻病人炎症反应,改善临床症状,提高病人生活质量,其疗效确切。     

The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19

ObjectivePresentation of a case illustrating the benefits of traditional Chinese medicine (TCM) for treatment of Coronavirus disease 2019 (COVID-19) in critically ill patients.Clinical features and outcomeA 58-year-old woman presented with cough, fever, dizziness, chest tightness, polypnea and poor appetite. She was admitted to Guizhou Provincial People’s hospital, and diagnosed with critically ill type of COVID-19 in February 2020. According to the patient's symptoms and signs, the TCM syndrome differentiation was qi deficiency, dampness-stasis and toxin accumulation. Then she received the combined therapy of a modified Chinese herbal formula and Western medicine. During a twelve-day period of treatment, her respiratory distress and appetite quickly improved. Abnormal laboratory indicators were resumed in time and lung lesions in CT scan largely absorbed. No side effects associated with this Chinese herbal formula were found. Before discharge, two consecutive nasopharyngeal swabs were shown to be negative for severe acute respiratory coronavirus 2 (SARS-CoV-2).ConclusionsOur case report suggests that collaborative treatments with traditional Chinese medicine prove beneficial in the management of COVID-19 in critically ill patients. In order to give optimal care for this COVID-19 crisis for the whole world, Chinese medicine practitioners and Western medical doctors should work together in frontline.     

Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis

BackgroundMany patients with multiple sclerosis (MS) resort to complementary and alternative medicine, which is used in 33%–80% of MS patients in the developed country. The purpose of this study is to assess the efficacy and safety of Chinese herbal medicine (CHM) as an adjunct therapy of patients with acute relapse of MS.MethodsSix databases were searched for randomized-controlled trial of CHM for acute relapse of MS. The risk of bias was assessed by using the twelve criteria recommended by the Cochrane Back Review Group. The primary outcome measures of interest are the Expanded Disability Status Score, annual relapse frequency, annual relapse rate, and annual relapse interval. The secondary outcome measures are the clinical efficacy rate and adverse events. The selection criteria of high-frequency herbs for MS are those with cumulative frequency over 50%. We analyzed the data using Review Manager (version 5.3).ResultsA total of 1100 participants were included in the 20 studies from 2004 to 2015. The number of risk of bias which met the criteria varied from 5/12 to 7/12. The top 5 most frequently used herbs are ordinally Radix Angelicae Sinensis, Radix Glycyrrhizae, Radix Paeoniae Rubra, Radix Rehmanniae Preparata, and Bombyx Batryticatus. The meta-analysis showed a significant effect of CHM for improving Expanded Disability Status Score (P < 0.01), annual relapse frequency (P < 0.01) and the total clinical efficacy rate (P < 0.01) compared with western conventional treatment. In analysis of annual relapse rate and annual relapse interval, there was a significant difference between CHMs and western conventional treatment (P < 0.01). Adverse effects were monitored in 6 studies, and were well tolerated in all MS patients.ConclusionsThe available evidence from present study supported but limited to recommend the routine use of CHM adjuvant therapy for MS because of the poor methodological quality and clinical heterogeneity. However, we identified an area that is worthy of further study. Furthermore, we selected high frequent use of CHMs as a promising candidate for further clinical application and MS trials. Further rigorous randomized-controlled trials are needed.